350 related articles for article (PubMed ID: 16888683)
1. Gene therapy and erectile dysfunction: the current status.
Lau DH; Kommu SS; Siddiqui EJ; Thompson CS; Morgan RJ; Mikhailidis DP; Mumtaz FH
Asian J Androl; 2007 Jan; 9(1):8-15. PubMed ID: 16888683
[TBL] [Abstract][Full Text] [Related]
2. Effect of PDE5 inhibition combined with free oxygen radical scavenger therapy on erectile function in a diabetic animal model.
De Young L; Yu D; Freeman D; Brock GB
Int J Impot Res; 2003 Oct; 15(5):347-54. PubMed ID: 14562136
[TBL] [Abstract][Full Text] [Related]
3. Treatment of erectile dysfunction.
Dinsmore W
Int J STD AIDS; 2004 Apr; 15(4):215-21. PubMed ID: 15075013
[TBL] [Abstract][Full Text] [Related]
4. Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidences.
Greco EA; Spera G; Aversa A
Eur Urol; 2006 Nov; 50(5):940-7. PubMed ID: 16979814
[TBL] [Abstract][Full Text] [Related]
5. Molecular pathophysiology and gene therapy of aging-related erectile dysfunction.
Gonzalez-Cadavid NF; Rajfer J
Exp Gerontol; 2004; 39(11-12):1705-12. PubMed ID: 15582286
[TBL] [Abstract][Full Text] [Related]
6. PDE5 inhibitors: are there differences?
Carson CC
Can J Urol; 2006 Feb; 13 Suppl 1():34-9. PubMed ID: 16526979
[TBL] [Abstract][Full Text] [Related]
7. Gene therapy for erectile dysfunction: fact or fiction?
Kendirci M; Teloken PE; Champion HC; Hellstrom WJ; Bivalacqua TJ
Eur Urol; 2006 Dec; 50(6):1208-22. PubMed ID: 16950560
[TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase type 5 inhibitors for erectile dysfunction.
Carson CC; Lue TF
BJU Int; 2005 Aug; 96(3):257-80. PubMed ID: 16042713
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic strategies for optimizing PDE-5 inhibitor therapy in patients with erectile dysfunction considered difficult or challenging to treat.
de Tejada IS
Int J Impot Res; 2004 Jun; 16 Suppl 1():S40-2. PubMed ID: 15224136
[TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase type 5 inhibitor therapy: identifying and exploring what attributes matter more to clinicians and patients in the management of erectile dysfunction.
Axilrod AC
Curr Med Res Opin; 2007 Dec; 23(12):3189-98. PubMed ID: 17991309
[TBL] [Abstract][Full Text] [Related]
11. [Novel indications for phosphodiesterase type 5 inhibitors].
Rosenkranz S; Caglayan E; Erdmann E
Med Klin (Munich); 2007 Aug; 102(8):617-30. PubMed ID: 17694282
[TBL] [Abstract][Full Text] [Related]
12. Evaluating preference trials of oral phosphodiesterase 5 inhibitors for erectile dysfunction.
Mulhall JP; Montorsi F
Eur Urol; 2006 Jan; 49(1):30-7. PubMed ID: 16263207
[TBL] [Abstract][Full Text] [Related]
13. Long-term continuous treatment with sildenafil ameliorates aging-related erectile dysfunction and the underlying corporal fibrosis in the rat.
Ferrini MG; Kovanecz I; Sanchez S; Vernet D; Davila HH; Rajfer J; Gonzalez-Cadavid NF
Biol Reprod; 2007 May; 76(5):915-23. PubMed ID: 17287493
[TBL] [Abstract][Full Text] [Related]
14. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.
Ravipati G; McClung JA; Aronow WS; Peterson SJ; Frishman WH
Cardiol Rev; 2007; 15(2):76-86. PubMed ID: 17303994
[TBL] [Abstract][Full Text] [Related]
15. Phosphodiesterase 5 mechanisms and therapeutic applications.
Burnett AL
Am J Cardiol; 2005 Dec; 96(12B):29M-31M. PubMed ID: 16387563
[TBL] [Abstract][Full Text] [Related]
16. Phosphodiesterase type 5 inhibitors' extended duration of response as a variable in the treatment of erectile dysfunction.
Dunn ME; Althof SE; Perelman MA
Int J Impot Res; 2007; 19(2):119-23. PubMed ID: 16738695
[TBL] [Abstract][Full Text] [Related]
17. Rationale for phosphodiesterase 5 inhibitor use post-radical prostatectomy: experimental and clinical review.
Rambhatla A; Kovanecz I; Ferrini M; Gonzalez-Cadavid NF; Rajfer J
Int J Impot Res; 2008; 20(1):30-4. PubMed ID: 17673932
[TBL] [Abstract][Full Text] [Related]
18. Molecular pharmacotherapeutic targeting of PDE5 for preservation of penile health.
Burnett AL
J Androl; 2008; 29(1):3-14. PubMed ID: 17942972
[TBL] [Abstract][Full Text] [Related]
19. Phosphodiesterase type 5 inhibithors in older males.
Frajese GV; Pozzi F
J Endocrinol Invest; 2005; 28(11 Suppl Proceedings):112-5. PubMed ID: 16760638
[TBL] [Abstract][Full Text] [Related]
20. New achievement and novel therapeutic applications of PDE5 inhibithors in older males.
Frajese GV; Pozzi F
J Endocrinol Invest; 2005; 28(3 Suppl):45-50. PubMed ID: 16042360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
